A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Trial Profile

A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Bendamustine; Dacarbazine
  • Indications Hodgkin's disease
  • Focus Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 16 Oct 2017 According to results published in the Blood, the sponsor of this study decided to suspend bendamustine treatment and enrollment in this arm due to ongoing toxicities.
    • 16 Oct 2017 According to results published in the Blood, a protocol was amended to reduce bendamustine dosing to 70 mg/m2 due to the number of serious adverse events.
    • 16 Oct 2017 Results of cohorts of patients who received brentuximab vedotin + dacarbazine (n=22) and brentuximab vedotin + bendamustine (n=20) published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top